• admin@ataxiatelangiectasia.es
Ataxia-telangiectasia
  • Início
  • O que é A-T?
  • Notícias

Bibliography

  • NAD+ Replenishment Improves Lifespan and Healthspan in Ataxia Telangiectasia Models via Mitophagy and DNA Repair.
    Acessos: 255
    • United States of America
    • 2016
    • Australia
    • Li J
    • Fang EF
    • Bohr VA
    • Cell Metab
    • Kassahun H
    • Croteau DL
    • Scheibye-Knudsen M
    • Marosi K
    • Lu H
    • Shamanna RA
    • Kalyanasundaram S
    • Bollineni RC
    • Wilson MA
    • Iser WB
    • Wollman BN
    • Morevati M
    • Kerr JS
    • Lu Q
    • Waltz TB
    • Tian J
    • Sinclair DA
    • Mattson MP
    • Nilsen H
    • Norway
    • Denmark
    • mytochondrial disfunction
    • mitophagy
    • NAD+
    Cell Metab. 2016 Oct 11;24(4):566-581. doi: 10.1016/j.cmet.2016.09.004.
    Fang EF1, Kassahun H2, Croteau DL1, Scheibye-Knudsen M3, Marosi K4, Lu H1, Shamanna RA1, Kalyanasundaram S5, Bollineni RC6, Wilson MA4, Iser WB4, Wollman BN1, Morevati M3, Li J7, Kerr JS1, Lu Q1, Waltz TB1, Tian J1, Sinclair DA8, Mattson MP9, Nilsen H2, Bohr VA10.

    Author information

    1
    Laboratory of Molecular Gerontology, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
    2
    Institute of Clinical Medicine, University of Oslo and Akershus University Hospital, 1478 Lørenskog, Norway.
    3
    Laboratory of Molecular Gerontology, National Institute on Aging, NIH, Baltimore, MD 21224, USA; Danish Center for Healthy Aging, University of Copenhagen, Copenhagen, Blegdamsvej 3B 2200, Denmark.
    4
    Laboratory of Neurosciences, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
    5
    Institute of Clinical Medicine, University of Oslo and Akershus University Hospital, 1478 Lørenskog, Norway; Bioinformatics Core Facility, Department of Core Facilities, Institute of Cancer Research, Radium Hospital, Oslo University Hospital, 0379 Oslo, Norway.
    6
    Department of Biosciences, University of Oslo, 0316 Oslo, Norway.
    7
    Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
    8
    Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Department of Pharmacology, School of Medical Sciences, University of New South Wales, Sydney NSW 2052, Australia.
    9
    Laboratory of Neurosciences, National Institute on Aging, NIH, Baltimore, MD 21224, USA; Department of Neuroscience, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
    10
    Laboratory of Molecular Gerontology, National Institute on Aging, NIH, Baltimore, MD 21224, USA; Danish Center for Healthy Aging, University of Copenhagen, Copenhagen, Blegdamsvej 3B 2200, Denmark. Electronic address: vbohr@nih.gov.

    Abstract

    Ataxia telangiectasia (A-T) is a rare autosomal recessive disease characterized by progressive neurodegeneration and cerebellar ataxia. A-T is causally linked to defects in ATM, a master regulator of the response to and repair of DNA double-strand breaks. The molecular basis of cerebellar atrophy and neurodegeneration in A-T patients is unclear. Here we report and examine the significance of increased PARylation, low NAD+, and mitochondrial dysfunction in ATM-deficient neurons, mice, and worms. Treatments that replenish intracellular NAD+ reduce the severity of A-T neuropathology, normalize neuromuscular function, delay memory loss, and extend lifespan in both animal models. Mechanistically, treatments that increase intracellular NAD+ also stimulate neuronal DNA repair and improve mitochondrial quality via mitophagy. This work links two major theories on aging, DNA damage accumulation, and mitochondrial dysfunction through nuclear DNA damage-induced nuclear-mitochondrial signaling, and demonstrates that they are important pathophysiological determinants in premature aging of A-T, pointing to therapeutic interventions.

    Comment in

    • Overcoming ATM Deficiency by Activating the NAD+/SIRT1 Axis. [Cell Metab. 2016]
    PMID:
     
    27732836
     
    PMCID:
     
    PMC5777858
     
    DOI:
     
    10.1016/j.cmet.2016.09.004
    [Indexed for MEDLINE] 
    Free PMC Article
  • Overcoming ATM Deficiency by Activating the NAD+/SIRT1 Axis.
    Acessos: 244
    • United States of America
    • DNA repair
    • Cell Metab
    • NAD+
    • Guarente L
    • mitochondrial dysfunction

    Send to

    Cell Metab. 2016 Oct 11;24(4):526-528. doi: 10.1016/j.cmet.2016.09.019.
    Guarente L1.

    Author information

    1
    Novartis Professor, Koch Institute Affiliate and Director of the Paul F. Glenn Center for the Science of Aging Research, MIT, Cambridge, MA 02139, USA. Electronic address: leng@mit.edu.

    Abstract

    In this issue, Fang et al. (2016) show that both the DNA repair defect and mitochondrial dysfunction in ATM-/- cells or mice are mitigated by the anti-aging compound nicotinamide riboside or a SIRT1 activator. This broad suppression by activating the NAD+/SIRT1 axis may generally apply to diseases and aging maladies.

    Comment on

    • NAD<sup>+</sup> Replenishment Improves Lifespan and Healthspan in Ataxia Telangiectasia Models via Mitophagy and DNA Repair. [Cell Metab. 2016]
    PMID:
     
    27732834
     
    DOI:
     
    10.1016/j.cmet.2016.09.019
    [Indexed for MEDLINE] 
    Free full text
  • Validation of a flow cytometry-based detection of γ-H2AX, to measure DNA damage for clinicalapplications.
    Acessos: 245
    • ataxia telangiectasia
    • 2017
    • Sweden
    • DNA double-strand break repair
    • Flow cytometry
    • Ionizing radiation
    • Cytometry B Clin Cytom
    • Johansson P
    • Fasth A
    • Ek T
    • Hammarsten O
    • H2AX
    • gamma-H2AX
    • intrinsic radiation sensitivity
    Cytometry B Clin Cytom. 2017 Nov;92(6):534-540. doi: 10.1002/cyto.b.21374. Epub 2016 May 24.
    Johansson P1, Fasth A2, Ek T3, Hammarsten O1.

    Author information

    1
    Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
    2
    Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
    3
    Department of Pediatrics, Hospital of Halland, Halmstad, Sweden.

    Abstract

    BACKGROUND:

    The nucleosomal histone protein H2AX is specifically phosphorylated (γ-H2AX) adjacent to DNA double-strand breaks (DSBs) and is used for quantifying DSBs. Many chemotherapies and ionizing radiation (IR) used in cancer treatment result in DSBs. Therefore, γ-H2AX has a significant potential as a biomarker in evaluating patient sensitivity and responsiveness to IR and chemotherapy.

    METHODS:

    Here, we report a flow cytometry-based quantification of γ-H2AX (FCM-γ-H2AX assay) customized for clinical practice.

    RESULTS:

    We validated that our method is able to detect DNA damage in peripheral blood mononuclear cells (PBMCs) treated with DSB inducing agents. The method also detected the DNA repair deficiency in PBMCs treated with DNA repair inhibitors, as well as the deficiency in DNA repair signaling in PBMCs from two ataxia telangiectasia patients.

    CONCLUSIONS:

    The FCM-γ-H2AX assay has sufficient analytical sensitivity and precision to measure levels of DNA damage and DNA repair for clinical purposes. © 2016 International Clinical Cytometry Society.

    © 2016 International Clinical Cytometry Society.

    KEYWORDS:

    DNA double-strand break (DSB); H2AX; ataxia telangiectasia (AT); drug sensitivity; flow cytometry (FCM); gamma-H2AX; intrinsic radiation sensitivity; ionizing radiation (IR)

    PMID:
     
    27060560
     
    DOI:
     
    10.1002/cyto.b.21374
    [Indexed for MEDLINE]
  • A flow cytometry assay that measures cellular sensitivity to DNA-damaging agents, customized for clinical routine laboratories.
    Acessos: 277
    • 2016
    • Sweden
    • Flow cytometry
    • Gao Y
    • Johansson P
    • Fasth A
    • Ek T
    • Hammarsten O
    • intrinsic radiation sensitivity
    • Clin Biochem
    • Mathew ST
    • Cell division
    • Clonogenic assay
    • DNA-damaging agents
    • Drug sensitivity

    Send to

     
    Clin Biochem. 2016 May;49(7-8):566-72. doi: 10.1016/j.clinbiochem.2016.01.009. Epub 2016 Jan 15.
    Mathew ST1, Johansson P1, Gao Y1, Fasth A2, Ek T3, Hammarsten O4.

    Author information

    1
    Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
    2
    Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
    3
    Department of Pediatrics, Hospital of Halland, Halmstad, Sweden.
    4
    Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. Electronic address: ola.hammarsten@clinchem.gu.se.

    Abstract

    OBJECTIVES:

    The clonogenic assay examines cell sensitivity to toxic agents and has been shown to correlate with normal tissue sensitivity to radiotherapy in cancer patients. The clonogenic assay is not clinically applicable due to its intra-individual variability and the time frame of the protocol. We aimed to develop a clinically applicable assay that correlated with the clonogenic assay.

    DESIGN AND METHODS:

    We have developed a faster and less labor-intensive cell division assay (CD assay) using flow cytometry and incorporation of a fluorescent thymidine analogue. The CD assay was calibrated to the clonogenic assay and optimized for peripheral blood lymphocytes.

    RESULTS:

    Following ionizing radiation of primary human skin fibroblasts, the four-day CD assay gave similar results as the 14-day clonogenic survival assay. In lymphocytes isolated from patient blood samples, the CD assay was able to detect increased radiosensitivity in ataxia telangiectasia patients and increased radiosensitivity after in vitro treatment with DNA-PK and ATM inhibitors. The CD assay found a variation in the intrinsic radiosensitivity of lymphocytes isolated from healthy control samples. The CD assay was able to measure the anti-proliferation effect of different chemotherapeutic drugs in lymphocytes.

    CONCLUSIONS:

    Our results indicate that the CD assay is a fast and reliable method to measure the anti-proliferation effect of DNA-damaging agents with a potential to find the most sensitive patients in the work-up before cancer treatment.

    Copyright © 2016. Published by Elsevier Inc.

    KEYWORDS:

    Cell division; Clonogenic assay; DNA-damaging agents; Drug sensitivity; Intrinsic radiation sensitivity

    PMID:
     
    26779995
     
    DOI:
     
    10.1016/j.clinbiochem.2016.01.009
    [Indexed for MEDLINE]
  • Ataxia-telangiectasia - A historical review and a proposal for a new designation: ATM syndrome.
    Acessos: 229
    • ataxia telangiectasia
    • Canada
    • United States of America
    • Brazil
    • 2015
    • Teive HAG
    • Munhoz RP
    • immunodeficiency
    • J Neurol Sci
    • malignancies
    • cerebellar ataxia
    • Moro A
    • Moscovich M
    • Arruda WO
    • Raskin S
    • Ashizawa T
    • Alpha-fetoprotein
    • Oculocutaneous telangiectasia
    J Neurol Sci. 2015 Aug 15;355(1-2):3-6. doi: 10.1016/j.jns.2015.05.022. Epub 2015 May 29.
    Teive HA1, Moro A2, Moscovich M2, Arruda WO2, Munhoz RP3, Raskin S4, Ashizawa T5.

    Author information

    1
    Movement Disorders Unit, Neurology Service, Internal Medicine Department, Hospital de Clínicas, Federal University of Paraná, Curitiba, PR, Brazil. Electronic address: hagteive@mps.com.br.
    2
    Movement Disorders Unit, Neurology Service, Internal Medicine Department, Hospital de Clínicas, Federal University of Paraná, Curitiba, PR, Brazil.
    3
    Movement Disorders Centre, Toronto Western Hospital, Toronto University, Toronto, ON, Canada.
    4
    Genetika Laboratory, Curitiba, PR, Brazil.
    5
    Neurology Department and McKnight Brain Institute, University of Florida, Gainesville, FL, USA.

    Abstract

    The authors review ataxia telangiectasia, emphasizing historical aspects, genetic discoveries, and the clinical presentations of the classical and atypical forms. In fact, ataxia telangiectasia represents a multisystem entity with pleomorphic neurological and systemic manifestations. ATM syndrome is proposed as a more adequate designation for this entity.

    KEYWORDS:

    Alpha-fetoprotein; Ataxia-telangiectasia; Cerebellar ataxia; Immunodeficiency; Malignancies; Oculocutaneous telangiectasia

    PMID:
     
    26050521
     
    PMCID:
     
    PMC5161405
     
    DOI:
     
    10.1016/j.jns.2015.05.022
    [Indexed for MEDLINE] 
    Free PMC Article
  • FVC deterioration, airway obstruction determination, and life span in Ataxia telangiectasia.
    Acessos: 254
    • ataxia telangiectasia
    • Sarouk I
    • 2015
    • Vilozni D
    • Lavie M
    • Alcaneses Ofek MR
    • Efrati O
    • spirometry
    • Respir Med
    • Bar-Aluma BE
    • Dagan A
    • Ashkenazi M
    • Airway obstruction
    Respir Med. 2015 Jul;109(7):890-6. doi: 10.1016/j.rmed.2015.05.013. Epub 2015 May 21.
    Vilozni D1, Lavie M2, Sarouk I2, Bar-Aluma BE2, Dagan A2, Ashkenazi M2, Ofek M2, Efrati O2.

    Author information

    1
    The Pediatric Pulmonary Unit and the Ataxia Telangiectasia National Clinic, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Israel. Electronic address: daphna.vilozni@sheba.health.gov.il.
    2
    The Pediatric Pulmonary Unit and the Ataxia Telangiectasia National Clinic, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Israel.

    Abstract

    RATIONALE:

    Forced vital capacity (FVC) values decrease with progress of the disease in Ataxia telangiectasia (AT).

    OBJECTIVE:

    To study the effect of this process on airway obstruction determination and life span in AT.

    METHODS:

    Clinical data and yearly best spirometry maneuvers were collected retrospectively from 37 AT patients (196 spirometry tests) during 5.4 ± 1.8yrs (initial age 4-21 y). Twelve patients were walking (7 of them had recurrent respiratory system infections); 25 subjects were confined to wheelchair, of them 8 patients were towards end-stage lung disease. Spirometry indices included Forced Vital Capacity (FVC), mid-expiratory-flow (FEF25-75), and tidal volume (VT). We calculated FEF25-75/FVC and VT/FVC ratios.

    RESULTS:

    FVC declined from 67 ± 8 while walking to 19 ± 6 %predicted values. FEF25-75 values that were elevated (116 ± 23 %predicted) while walking, decreased to 69 ± 27 %predicted at end-stage where 7 patients responded to bronchodilators. VT/FVC ratio was 0.25 ± 0.06 while walking, increased to 0.35 once on wheelchairs, and further increased to 0.57 ± 0.19 at end-stage disease. FEF25-75/FVC ratio was 2.54 ± 0.70 above normal (∼1.0) increasing to 4.16 ± 0.75 at end stage. A sharp elevation was seen in FEF25-75/FVC ratio when FEV1 was still ∼45 %predicted and 2-years prior to death.

    CONCLUSIONS:

    Having a low baseline-FVC (60% predicted) artificially raises FEF25-75 values, so FEF25-75 of "mild obstruction" values may indicate severe airway obstruction in AT subjects. VT/FVC and FEF25-75/FVC ratios may therefore assist in revealing higher than normal breathing effort. The results further suggest adding VT/FVC and FEF25-75/FVC ratios to pulmonary function assessments in patients with AT.

    Copyright © 2015 Elsevier Ltd. All rights reserved.

    KEYWORDS:

    Airway obstruction; Ataxia telangiectasia; Spirometry

    PMID:
     
    26033643
     
    DOI:
     
    10.1016/j.rmed.2015.05.013
    [Indexed for MEDLINE] 
    Free full text
  • Recognition of genetic predisposition in pediatric cancer patients: An easy-to-use selection tool
    Acessos: 249
    • The Netherlands
    • 2016
    • Eur J Med Genet
    • Jongmans MC
    • Hoogerbrugge N
    • Loeffen JL
    • Waanders E
    • Hoogerbrugge PM
    • Ligtenberg MJ
    • Kuiper RP
    • Cancer susceptibility
    • Childhood cancer
    • Congenital anomalies
    • Dysmorphisms
    • Family history
    • Selection tool
    Eur J Med Genet. 2016 Mar;59(3):116-25. doi: 10.1016/j.ejmg.2016.01.008. Epub 2016 Jan 26.
    Jongmans MC1, Loeffen JL2, Waanders E3, Hoogerbrugge PM4, Ligtenberg MJ3, Kuiper RP3, Hoogerbrugge N3.

    Author information

    1
    Department of Human Genetics, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands. Electronic address: marjolijn.jongmans@radboudumc.nl.
    2
    Department of Pediatric Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.
    3
    Department of Human Genetics, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
    4
    Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

    Abstract

    Genetic predisposition for childhood cancer is under diagnosed. Identifying these patients may lead to therapy adjustments in case of syndrome-related increased toxicity or resistant disease and syndrome-specific screening programs may lead to early detection of a further independent malignancy. Cancer surveillance might also be warranted for affected relatives and detection of a genetic mutation can allow for reproductive counseling. Here we present an easy-to-use selection tool, based on a systematic review of pediatric cancer predisposing syndromes, to identify patients who may benefit from genetic counseling. The selection tool involves five questions concerning family history, the type of malignancy, multiple primary malignancies, specific features and excessive toxicity, which results in the selection of those patientsthat may benefit from referral to a clinical geneticist.

    KEYWORDS:

    Cancer susceptibility; Childhood cancer; Congenital anomalies; Dysmorphisms; Family history; Selection tool

    PMID:
     
    26825391
     
    DOI:
     
    10.1016/j.ejmg.2016.01.008
    [Indexed for MEDLINE] 
    Free full text
     
  • Premature ageing of the immune system underlies immunodeficiency in ataxia telangiectasia.
    Acessos: 281
    • United Kingdom
    • 2011
    • ATM kinase
    • Taylor AMR
    • Byrd P
    • Clin Immunol
    • Exley AR
    • Buckenham S
    • Hodges E
    • Hallam R
    • Last J
    • Trinder C
    • Harris S
    • Screaton N
    • Williams AP
    • Shneerson JM
    • premature ageing
    • immunodeficiency
    Clin Immunol. 2011 Jul;140(1):26-36. doi: 10.1016/j.clim.2011.03.007. Epub 2011 Mar 13.

    Premature ageing of the immune system underlies immunodeficiency in ataxia telangiectasia.

    Exley AR1, Buckenham S, Hodges E, Hallam R, Byrd P, Last J, Trinder C, Harris S, Screaton N, Williams AP, Taylor AM, Shneerson JM.

    Author information

    1
    Immunology Laboratory, Department of Pathology, Papworth Hospital NHS Foundation Trust, Cambridge University Health Partners, Cambridge CB23 3RE, UK. andrew.exley@papworth.nhs.uk

    Abstract

    ATM kinase modulates pathways implicated in premature ageing and ATM genotype predicts survival, yet immunodeficiency in ataxiatelangiectasia is regarded as mild and unrelated to age. We address this paradox in a molecularly characterised sequential adult cohort with classical and mild variant ataxia telangiectasia. Immunodeficiency has the characteristics of premature ageing across multiple cellular and molecular immune parameters. This immune ageing occurs without previous CMV infection. Age predicts immunodeficiency in genetically homogeneous ataxia telangiectasia, and in comparison with controls, calendar age is exceeded by immunological age defined by thymic naïve CD4+ T cell levels. Applying ataxia telangiectasia as a model of immune ageing, pneumococcal vaccine responses, characteristically deficient in physiological ageing, are predicted by thymic naïve CD4+ T cell levels. These data suggest inherited defects of DNA repair may provide valuable insight into physiological ageing. Thymic naïve CD4+ T cells may provide a biomarker for vaccine responsiveness in elderly cohorts.

    PMID:
     
    21459046
     
    DOI:
     
    10.1016/j.clim.2011.03.007
  • Spontaneous pneumothorax in ataxia telangectasia.
    Acessos: 265
    • India
    • 2014
    • Indian J Med Res
    • Chakravarthi S
    • Goyal MK
    • pneumotorax
    Indian J Med Res. 2014 Aug;140(2):321-2.
    Chakravarthi S1, Goyal MK.

    Author information

    1
    Department of Neurology, Postgraduate Institute of Medical Education & Research Sector-12, Chandigarh 160 012, India.
    PMID:
     
    25297371
     
    PMCID:
     
    PMC4216512
    [Indexed for MEDLINE] 
    Free PMC Article
  • Evaluation and management of pulmonary disease in ataxia-telangiectasia.
    Acessos: 250
    • United States of America
    • 2010
    • McGrath-Morrow SA
    • Lederman HM
    • Lefton-Greif MA
    • Crawford TO
    • Rothblum-Oviatt C
    • Sandlund JT
    • Pediatr Pulmonol
    • Gower WA
    • Brody AS
    • Langston C
    • Fan LL
    • Troche M
    • Auwaerter PG
    • Easley B
    • Loughlin GM
    • Carroll JL
    Pediatr Pulmonol. 2010 Sep;45(9):847-59. doi: 10.1002/ppul.21277.

    McGrath-Morrow SA1, Gower WA, Rothblum-Oviatt C, Brody AS, Langston C, Fan LL, Lefton-Greif MA, Crawford TO, Troche M, Sandlund JT, Auwaerter PG, Easley B, Loughlin GM, Carroll JL, Lederman HM.

    Author information

     

    Abstract

    Ataxia-telangiectasia (A-T) is a rare autosomal recessive disorder caused by mutations in the ATM gene, resulting in faulty repair of breakages in double-stranded DNA. The clinical phenotype is complex and is characterized by neurologic abnormalities, immunodeficiencies, susceptibility to malignancies, recurrent sinopulmonary infections, and cutaneous abnormalities. Lung disease is common in patients with A-T and often progresses with age and neurological decline. Diseases of the respiratory system cause significant morbidity and are a frequent cause of death in the A-T population. Lung disease in this population is thought to exhibit features of one or more of the following phenotypes: recurrent sinopulmonary infections with bronchiectasis, interstitial lung disease, and lung disease associated with neurological abnormalities. Here, we review available evidence and present expert opinion on the diagnosis, evaluation, and management of lung disease in A-T, as discussed in a recent multidisciplinary workshop. Although more data are emerging on this unique population, many recommendations are made based on similarities to other more well-studied diseases. Gaps in current knowledge and areas for future research in the field of pulmonary disease in A-T are also outlined.

    PMID:
     
    20583220
     
    PMCID:
     
    PMC4151879
     
    DOI:
     
    10.1002/ppul.21277
    [Indexed for MEDLINE] 
    Free PMC Article
  • Survival probability in ataxia telangiectasia.
    Acessos: 231
    • United States of America
    • Lederman HM
    • Survival
    • neurological impairment
    • Arch Dis Child
    • Crawford TO
    • Skolasky RL
    • Fernandez R
    • Rosquist KJ
    • 2006
    Arch Dis Child. 2006 Jul;91(7):610-1.
    Crawford TO1, Skolasky RL, Fernandez R, Rosquist KJ, Lederman HM.

    Author information

    1
    Department of Neurology, The Johns Hopkins Hospital, Baltimore, Maryland 21287, USA. tcrawfo@jhmi.edu

    Abstract

    Ataxia telangiectasia is a rare, multiorgan neurodegenerative disorder with enhanced vulnerability to cancer and infection. Median survival in two large cohorts of patients with this disease, one prospective and one retrospective, is 25 and 19 years, with a wide range. Life expectancy does not correlate well with severity of neurological impairment.

    PMID:
     
    16790721
     
    PMCID:
     
    PMC2082822
     
    DOI:
     
    10.1136/adc.2006.094268
    [Indexed for MEDLINE] 
    Free PMC Article
  • Extracerebellar MRI-lesions in ataxia telangiectasia go along with deficiency of the GH/IGF-1 axis, markedly reduced body weight, high ataxia scores and advanced age.
    Acessos: 246
    • Schubert R
    • Zielen S
    • 2010
    • Neurodegeneration
    • Kieslich M
    • Cerebellum
    • Hoche F
    • Reichenbach J
    • Weidauer S
    • Porto L
    • Vlaho S
    • weight
    • GH/IGF-1 axis
    • body weight
    • ataxia scores
    Cerebellum. 2010 Jun;9(2):190-7. doi: 10.1007/s12311-009-0138-0.
    Kieslich M1, Hoche F, Reichenbach J, Weidauer S, Porto L, Vlaho S, Schubert R, Zielen S.

    Author information

    1
    Department of Pediatrics, Goethe University Frankfurt, Germany.

    Abstract

    Ataxia telangiectasia (AT) is a rare autosomal recessive disorder characterized by progressive ataxia, neurodegeneration, immunodeficiency, and cancer predisposition. Pathoanatomical studies reported a degeneration of cerebellar Purkinje cells as the striking feature of the disease. Although recent studies suggested the involvement of extracerebellar structures such as the brainstem and basal ganglia, this has rarely been studied in human AT. Thus, we performed a detailed cliniconeuroradiological investigation of 11 AT patients, aged 8 to 26 years by collecting clinical neurological data, ataxia scores, growth status, body mass index (BMI), growth hormone (GH), and insulin-like-growth factor 1 (IGF-1) and correlated them to extracerebellar neuroimaging findings in human AT. Neuroimaging was done by cranial and spine magnetic resonance imaging (MRI) with T1- and T2-weighted spin-echo and fluid attenuated inversion recovery sequences. We compared clinical and neuroradiological findings of six patients with IGF-1 levels and BMI below the third percentile to five patients with normal IGF-1 serum levels and BMI above the third percentile. Three of the six first mentioned patients older than 20 years and two patients older than 12 years showed noticeable high Klockgether ataxia scores above 25 points. Three of these patients presented with marked hyperintense lesions in the cerebral white matter of T2-weighted MR images. Interestingly, all six patients suffered from marked spinal atrophy. Two of the patients presented with severe extra-pyramidal symptoms, but only one patient showed associated MRI abnormalities of the basal ganglia. MRI in patients with normal IGF-1 levels showed the expected cerebellar lesions in four patients, whereas spinal atrophy was found only in two patients. There was no affection of the cerebral white matter or basal ganglia in this group. We conclude that central cerebral white matter affection, spinal atrophy, and extrapyramidal symptoms are more often present in patients with pronounced deficiency of the GH/IGF-1 axis accompanied by markedly reduced body weight and high ataxia scores. This may point to a major role of IGF-1 and nutritional status in neuroprotective signaling.

    PMID:
     
    19898915
     
    DOI:
     
    10.1007/s12311-009-0138-0
    [Indexed for MEDLINE]
  • Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia.
    Acessos: 255
    • United States of America
    • Lavin MF
    • Australia
    • Gatti RA
    • Treatment
    • Br Med Bull
    • Gueven N
    • Bottle S
    Br Med Bull. 2007;81-82:129-47. Epub 2007 Jun 23.

    Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia.

    Lavin MF1, Gueven N, Bottle S, Gatti RA.

    Author information

    1
    Queensland Institute of Medical Research, Brisbane, Queensland, Australia. martinl@qimr.edu.au

    Abstract

    Ataxia-telangiectasia (A-T) is a rare autosomal recessive genetic disorder characterized by progressive neurodegeneration, a high risk of cancer and immunodeficiency. These patients are also hypersensitive to radiotherapy. The gene product defective in this syndrome, ATM (ataxia-telangiectasia mutated), normally recognizes DNA damage and signal to the DNA repair machinery and the cell cycle checkpoints to minimize the risk of genetic damage. No curative strategy for this disease exists. Treatment has focused on slowing the progress of the neurodegeneration; devising approaches for the treatment of tumours while minimizing side effects and treatment with immunoglobulin for the immunodeficiency. The most debilitating feature of this disorder is the progressive neurodegeneration due to loss of Purkinje cells in the cerebellum and malfunction of other neuronal cells. Correcting for the loss of Purkinje cells is technically very difficult and would require transplantation of embryonic stem cells. However, since it seems likely that oxidative stress may contribute to the neurodegeneration in A-T, potential therapies based on the use of antioxidants offer some hope. We describe the natural course of disease, some supportive therapeutic approaches already in use and those with potential based on our knowledge of molecular and cellular characteristics of this disorder.

    PMID:
     
    17586848
     
    DOI:
     
    10.1093/bmb/ldm012
    [Indexed for MEDLINE]
  • Elevated serum IL-8 levels in ataxia telangiectasia.
    Acessos: 241
    • United Kingdom
    • 2010
    • McGrath-Morrow SA
    • J Pediatr
    • Collaco JM
    • Lederman HM
    • IL-8
    • Lefton-Greif MA
    • Crawford TO
    • Carson KA
    • Zeitlin P
    J Pediatr. 2010 Apr;156(4):682-4.e1. doi: 10.1016/j.jpeds.2009.12.007. Epub 2010 Feb 20.
    McGrath-Morrow SA1, Collaco JM, Crawford TO, Carson KA, Lefton-Greif MA, Zeitlin P, Lederman HM.

    Author information

    1
    Division of Pediatric Pulmonology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA. smorrow@jhmi.edu

    Abstract

    Serum interleukin (IL)-8 levels were measured in 50 patients with ataxia telangiectasia (A-T) and 22 without A-T. In a cross-sectional study, the geometric mean of IL-8 level was significantly higher in the patients with A-T (P <.0001). Elevated serum IL-8 levels in patients with A-T suggest that systemic inflammation may contribute to the disease phenotype.

    PMID:
     
    20171651
     
    DOI:
     
    10.1016/j.jpeds.2009.12.007
    [Indexed for MEDLINE]
  • Growth factor deficiency in patients with ataxia telangiectasia.
    Acessos: 248
    • Schubert R
    • Zielen S
    • growth hormone
    • Reichenbach J
    • Clin Exp Immunol
    Clin Exp Immunol. 2005 Jun;140(3):517-9.
    Schubert R1, Reichenbach J, Zielen S.

    Author information

    1
    Department of Paediatrics, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany. ralf.schubert@kgu.de

    Abstract

    One prominent feature of patients with the autosomal recessive disease ataxia telangiectasia (AT) is somatic growth retardation. Due to their essential roles in development we examined levels of insulin-like growth factor-I (IGF-I) as well as its main binding protein (IGFBP-3) in a group of AT patients. Growth status of 19 patients was assessed by body mass index (BMI) and nutritional protocols. As suspected, BMI was low in AT patients despite adequate nutrition. Serum levels of IGF-I were found to be below the 3rd percentile in 9 (56%) out of 16 patientsand of IGFBP-3 in 13 (81%) out of 16 patients. Our observations demonstrate that IGF-I and IGFBP-3 levels reflect the impaired growthstatus in patients with AT.

    PMID:
     
    15932513
     
    PMCID:
     
    PMC1809398
     
    DOI:
     
    10.1111/j.1365-2249.2005.02782.x
    [Indexed for MEDLINE] 
    Free PMC Article
  • Variability of immunodeficiency associated with ataxia telangiectasia and clinical evolution in 12affected patients.
    Acessos: 258
    • Spain
    • immunodeficiency
    • Pediatr Allergy Immunol
    • immunodeficiency
    • Claret Teruel G
    • Giner Muñoz MT
    • Plaza Martín AM
    •  Martín Mateos MA
    • Piquer Gibert M
    • Sierra Martínez JI
    • 2005
    Pediatr Allergy Immunol. 2005 Nov;16(7):615-8.
    Claret Teruel G1, Giner Muñoz MT, Plaza Martín AM, Martín Mateos MA, Piquer Gibert M, Sierra Martínez JI.

    Author information

    1
    Allergy and Clinical Immunology Section, Paediatrics Department, Integrated Unit Sant Joan de Déu--Clínic, Hospital Universitari Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain. gclaret@hsjdbcn.org

    Abstract

    Ataxia telangiectasia (AT) is an infrequent condition, which is difficult to diagnose in children. The objective was to describe the evolution of all affected patients controlled in our hospital and to highlight the keys for an early diagnosis considering the variability of immunological disorders. The present study is a retrospective review of all patients diagnosed and controlled of AT in our hospital. Twelve patients were found, including two couples of siblings. The most frequent reason for consultation was unstable gait. Seven patients suffered repeated infections, being pneumonia the most frequent cause of infection, followed by sinusitis. One of the patients developed Burkitt's lymphoma, and another patient, Hodgkin's lymphoma, which caused the death of the patient at the age of 11. A couple of siblings aged 17 and 22 years developed insulin-resistant diabetes mellitus. The most frequent immunity disorders were the IgG deficiency and the decrease of T lymphocytes. Seven patients were treated with non-specific gamma-globulin. By the end of the follow-up, 8 patients (ages ranged 7 to 12years) lost gait. Molecular genetic testing was conducted in patients who are still cared for in our hospital. Clinical suspicion of this entity will lead to an early diagnosis, the treatment of complications, and to provide genetic counselling for the families.

    PMID:
     
    16238588
     
    DOI:
     
    10.1111/j.1399-3038.2005.00323.x
  • Ataxia-telangiectasia with female fertility.
    Acessos: 246
    • ataxia telangiectasia
    • 2015
    • Gatti RA
    • Am J Med Genet A
    • Dawson AJ
    • Marles S
    • Tomiuk M
    • Riordan D
    • female fertilitiy
    Am J Med Genet A. 2015 Aug;167A(8):1937-9. doi: 10.1002/ajmg.a.37084. Epub 2015 Apr 25.
    Dawson AJ1,2,3, Marles S2,3, Tomiuk M1, Riordan D1, Gatti RA4.

    Author information

    1
    Cytogenetic Laboratory/HSC, Diagnostic Services of Manitoba, Winnipeg, Manitoba, Canada.
    2
    Deptartments of Biochemistry & Medical Genetics and Pediatrics & Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.
    3
    Genetics & Metabolism Program, WRHA, Winnipeg, Manitoba, Canada.
    4
    Department of Pathology & Laboratory Medicine, and Human Genetics, UCLA/Geffen School of Medicine, Los Angeles, California.
    PMID:
     
    25914063
     
    DOI:
     
    10.1002/ajmg.a.37084
  • Brain glucose metabolism in adults with ataxia-telangiectasia and their asymptomatic relatives.
    Acessos: 256
    • United States of America
    • ATM
    • 2014
    • Crawford TO
    • Cerebellum
    • Volkow ND
    • Tomasi D
    • Wang GJ
    • Studentsova Y
    • Margus B
    • Brain
    • fusiform gyrus
    • globus pallidus
    • hippocampus
    Brain. 2014 Jun;137(Pt 6):1753-61. doi: 10.1093/brain/awu092. Epub 2014 Apr 17.
    Volkow ND1, Tomasi D2, Wang GJ2, Studentsova Y2, Margus B3, Crawford TO4.

    Author information

    1
    1 National Institute of Alcohol Abuse and Alcoholism, Rockville MD 20857, USA2 National Institute on Drug Abuse, Bethesda MD 20892, USA nvolkow@nida.nih.gov.
    2
    1 National Institute of Alcohol Abuse and Alcoholism, Rockville MD 20857, USA.
    3
    3 A-T Children's Project; 5300 W. Hillsboro Blvd, Suite 105, Coconut Creek FL 33073, USA.
    4
    4 Department of Neurology, Johns Hopkins University School of Medicine, Baltimore MD 21287, USA.

    Abstract

    Ataxia-telangiectasia is a recessive genetic disorder (ATM is the mutated gene) of childhood with severe motor impairments and whereas homozygotes manifest the disorder, heterozygotes are asymptomatic. Structural brain imaging and post-mortem studies in individuals with ataxia-telangiectasia have reported cerebellar atrophy; but abnormalities of motor control characteristic of extrapyramidal dysfunction suggest impairment of broader motor networks. Here, we investigated possible dysfunction in other brain areas in individuals with ataxia-telangiectasia and tested for brain changes in asymptomatic relatives to assess if heterozygocity affects brain function. We used positron emission tomography and (18)F-fluorodeoxyglucose to measure brain glucose metabolism (quantified as µmol/100 g/min), which serves as a marker of brain function, in 10 adults with ataxia-telangiectasia, 19 non-affected adult relatives (12 siblings, seven parents) and 29 age-matched healthy controls. Statistical parametric mapping and region of interest analyses were used to compare individuals with ataxia-telangiectasia, asymptomatic relatives, and unrelated controls. We found that participants with ataxia-telangiectasia had lower metabolism in cerebellar hemispheres (14%, P < 0.001), anterior vermis (40%, P < 0.001) and fusiform gyrus (20%, P < 0.001) compared with controls or siblings, and lower metabolism in hippocampus (12%, P = 0.05) compared with controls, and showed significant intersubject variability (decreases in vermis ranged from 18% to 60%). Participants with ataxia-telangiectasia also had higher metabolism in globus pallidus (16%, P = 0.05), which correlated negatively with motor performance. Asymptomatic relatives had lower metabolism in anterior vermis (12%; P = 0.01) and hippocampus (19%; P = 0.002) than controls. Our results indicate that, in addition to the expected decrease in cerebellar metabolism, participants with ataxia-telangiectasia had widespread changes in metabolic rates including hyperactivity in globus pallidus indicative of basal ganglia involvement. Changes in basal ganglia metabolism offer potential insight into targeting strategies for therapeutic deep brain stimulation. Our finding of decreased metabolism in vermis and hippocampus of asymptomatic relatives suggests that heterozygocity influences the function of these brain regions.

    KEYWORDS:

    ATM; ataxia telangiectasia mutated; cerebellum; fusiform gyrus; globus pallidus; hippocampus

    PMID:
     
    24747834
     
    PMCID:
     
    PMC4032102
     
    DOI:
     
    10.1093/brain/awu092
    [Indexed for MEDLINE] 
    Free PMC Article
  • Ataxia Telangiectasia (Louis-Bar Syndrome).
    Acessos: 313
    • 2018
    • United States of America
    • review
    • Riboldi GM
    • Frucht S
    • StatPearls

    Authors

    Riboldi GM1, Frucht S.

    Source

    StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018-.
    2018 Aug 18.

    Author information

    1
    New York University

    Excerpt

    Ataxia telangiectasia (A-T), also known as Louis-Bar Syndrome, is a rare genetic form of early-onset autosomal recessive ataxia. The clinical picture is characterized by a combination of neurological and systemic symptoms due to the mutation of the ataxia telangiectasia mutated (ATM) gene. In particular, the disease is characterized by cerebellar atrophy with progressive ataxia, cutaneous telangiectasias, higher incidence of malignancy (particularly lymphoid malignancy), radiosensitivity, immune deficiency, recurrent sinopulmonary infections, and high levels of alpha-fetoprotein in serum.

    Copyright © 2018, StatPearls Publishing LLC.

    Sections

    • Introduction
    • Etiology
    • Epidemiology
    • Pathophysiology
    • Histopathology
    • History and Physical
    • Evaluation
    • Treatment / Management
    • Differential Diagnosis
    • Prognosis
    • Pearls and Other Issues
    • Questions
    • References
    PMID:
     
    30137827
    Free Books & DocumentsFree full text
  • Bilateral maculopathy in a patient with ataxia telangiectasia.
    Acessos: 243
    • United States of America
    • 2016
    • eye movements
    • maculopathy
    • Gioia LV
    • Bonsall D
    • Moffett K
    • Leys M
    • J AAPOS
    J AAPOS. 2016 Feb;20(1):85-8. doi: 10.1016/j.jaapos.2015.10.005.
    Gioia LV1, Bonsall D2, Moffett K3, Leys M2.

    Author information

    1
    WVU School of Medicine, Morgantown, West Virginia. Electronic address: lgioia@mix.wvu.edu.
    2
    WVU Eye Institute, Morgantown, West Virginia.
    3
    WVU Pediatrics and WVU Infectious Diseases, Morgantown, West Virginia.

    Abstract

    We report a case of toxoplasmosis with bilateral maculopathy in a 7-year-old boy diagnosed with ataxia telangiectasia (AT) at age 6. AT manifests as ataxia, apraxia, telangiectasia, and dysarthria. Common ophthalmologic findings in AT include fine conjunctival telangiectasia. Patients also suffer from recurrent sinopulmonary infections; however, serious opportunistic infection is rarely diagnosed. At 8 years of age he developed disseminated Toxoplasma gondii (toxoplasmosis) infection and meningoencephalitis. This ophthalmologic finding and the subsequent toxoplasmosis meningoencephalitis have not been previously reported in AT.

    PMID:
     
    26917084
     
    DOI:
     
    10.1016/j.jaapos.2015.10.005
    [Indexed for MEDLINE]

Página 6 de 21

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10

Language

  Português Brasileiro (pt-BR)
  • Hindi (India)
  • Hebrew
  • Arabic (اللغة العربية)
  • Turkish (Turkey)
  • 日本語 (Japan)
  • Russian (Russia)
  • Français (France)
  • Deutsch (Deutschland)
  • Español (España)
  • Nederlands (nl-NL)
  • Português Brasileiro (pt-BR)
  • Polski (PL)
  • Italiano (Italia)
  • English (United Kingdom)

Tweets by A_Tinfo

Ataxia-telangiectasia
  • Início
  • O que é A-T?
  • Notícias
  • admin@ataxiatelangiectasia.es